Comparative Pharmacology
Head-to-head clinical analysis: DICHLORPHENAMIDE versus ETHAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICHLORPHENAMIDE versus ETHAMIDE.
DICHLORPHENAMIDE vs ETHAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dichlorphenamide is a carbonic anhydrase inhibitor. It inhibits the enzyme carbonic anhydrase in the proximal renal tubule, reducing reabsorption of bicarbonate, leading to metabolic acidosis, and decreasing intraocular pressure by reducing aqueous humor formation.
Ethamide is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye, lowering intraocular pressure. It also has diuretic effects by inhibiting carbonic anhydrase in the proximal renal tubule, leading to bicarbonate excretion and metabolic acidosis.
25-50 mg orally twice daily.
15-25 mg/kg orally once daily (max 1.5 g/day).
None Documented
None Documented
Terminal elimination half-life of 2-4 hours; increased in renal impairment, up to 12-24 hours in severe insufficiency.
Terminal elimination half-life is 4-6 hours in normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal via tubular secretion; 50-70% excreted unchanged in urine; minor biliary/fecal elimination (<20%).
Primarily renal (80-90%) as unchanged drug via glomerular filtration and tubular secretion; minor biliary/fecal (<5%) and metabolic (5-10%) elimination.
Category C
Category C
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor